Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALNY NASDAQ:BMRN NASDAQ:GMAB OTCMKTS:GNMSF OTCMKTS:UCBJF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNYAlnylam Pharmaceuticals$322.64+0.6%$300.06$205.87▼$333.70$41.84B0.23855,412 shs489,398 shsBMRNBioMarin Pharmaceutical$58.82-1.4%$57.51$52.93▼$94.85$11.44B0.171.74 million shs1.67 million shsGMABGenmab A/S$21.86+1.3%$21.04$17.24▼$28.56$13.84B0.941.24 million shs1.05 million shsGNMSFGenmab A/S$212.55-1.1%$208.09$170.00▼$292.80$14.21B0.9135 shs134 shsUCBJFUCB$203.85$183.05$149.85▼$209.66$38.53B0.47521 shs19 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNYAlnylam Pharmaceuticals+0.55%-2.80%+6.67%+35.69%+25.17%BMRNBioMarin Pharmaceutical-1.42%+2.74%+2.33%+3.52%-28.52%GMABGenmab A/S+1.30%+7.10%-4.29%+16.21%-14.97%GNMSFGenmab A/S-1.14%+7.07%-2.56%+16.43%-14.99%UCBJFUCB0.00%+2.01%+6.49%+35.27%+54.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALNYAlnylam Pharmaceuticals4.1558 of 5 stars2.44.00.04.32.82.50.6BMRNBioMarin Pharmaceutical4.9459 of 5 stars3.43.00.03.32.82.54.4GMABGenmab A/S4.1797 of 5 stars3.35.00.00.03.40.03.1GNMSFGenmab A/S0.8422 of 5 stars0.03.00.00.02.20.01.3UCBJFUCBN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALNYAlnylam Pharmaceuticals 2.80Moderate Buy$341.915.97% UpsideBMRNBioMarin Pharmaceutical 2.75Moderate Buy$93.6159.14% UpsideGMABGenmab A/S 2.67Moderate Buy$37.8072.92% UpsideGNMSFGenmab A/S 0.00N/AN/AN/AUCBJFUCB 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest BMRN, GNMSF, UCBJF, GMAB, and ALNY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025GMABGenmab A/STruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$45.00 ➝ $46.007/7/2025ALNYAlnylam PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$328.00 ➝ $384.007/3/2025BMRNBioMarin PharmaceuticalMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$97.006/30/2025ALNYAlnylam PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$287.00 ➝ $333.006/26/2025ALNYAlnylam PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$320.00 ➝ $377.006/24/2025ALNYAlnylam PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$300.00 ➝ $360.006/23/2025UCBJFUCBMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOverweight6/12/2025ALNYAlnylam PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$330.00 ➝ $338.005/5/2025BMRNBioMarin PharmaceuticalThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$124.00 ➝ $104.005/2/2025ALNYAlnylam PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$331.00 ➝ $349.005/2/2025ALNYAlnylam PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$300.00 ➝ $325.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALNYAlnylam Pharmaceuticals$2.25B18.71N/AN/A$0.52 per share620.46BMRNBioMarin Pharmaceutical$2.85B3.95$3.20 per share18.38$29.69 per share1.98GMABGenmab A/S$3.12B4.49$1.54 per share14.23$8.04 per share2.72GNMSFGenmab A/S$3.12B4.50$15.01 per share14.16$80.53 per share2.64UCBJFUCB$5.27B7.32$8.76 per share23.28$50.52 per share4.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALNYAlnylam Pharmaceuticals-$278.16M-$2.09N/A362.52N/A-11.49%-510.31%-6.48%8/7/2025 (Estimated)BMRNBioMarin Pharmaceutical$426.86M$2.6921.8713.490.8217.76%11.34%8.95%8/4/2025 (Estimated)GMABGenmab A/S$1.14B$1.7612.4212.286.5635.11%18.08%14.52%8/14/2025 (Estimated)GNMSFGenmab A/S$1.14B$17.6312.06∞N/A35.11%19.23%15.44%8/7/2025 (Estimated)UCBJFUCB$371.23MN/A0.0028.87N/AN/AN/AN/A7/23/2025 (Estimated)Latest BMRN, GNMSF, UCBJF, GMAB, and ALNY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ALNYAlnylam Pharmaceuticals-$0.0538N/AN/AN/A$633.54 millionN/A8/4/2025Q2 2025BMRNBioMarin Pharmaceutical$1.02N/AN/AN/A$761.51 millionN/A5/8/2025Q1 2025GMABGenmab A/S$0.23$0.31+$0.08$0.31$5.17 billion$715.00 million5/8/2025Q1 2025GNMSFGenmab A/S$1.88$3.05+$1.17$3.05$761.09 million$765.14 million5/1/2025Q1 2025ALNYAlnylam Pharmaceuticals-$0.37-$0.44-$0.07-$0.44$584.32 million$594.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALNYAlnylam PharmaceuticalsN/AN/AN/AN/AN/ABMRNBioMarin PharmaceuticalN/AN/AN/AN/AN/AGMABGenmab A/SN/AN/AN/AN/AN/AGNMSFGenmab A/SN/AN/AN/AN/AN/AUCBJFUCBN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALNYAlnylam Pharmaceuticals8.883.042.98BMRNBioMarin Pharmaceutical0.105.523.49GMABGenmab A/SN/A5.345.32GNMSFGenmab A/SN/A5.345.32UCBJFUCB0.331.190.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALNYAlnylam Pharmaceuticals92.97%BMRNBioMarin Pharmaceutical98.71%GMABGenmab A/S7.07%GNMSFGenmab A/SN/AUCBJFUCBN/AInsider OwnershipCompanyInsider OwnershipALNYAlnylam Pharmaceuticals1.50%BMRNBioMarin Pharmaceutical0.85%GMABGenmab A/S1.54%GNMSFGenmab A/S1.54%UCBJFUCBN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALNYAlnylam Pharmaceuticals2,230130.39 million128.43 millionOptionableBMRNBioMarin Pharmaceutical3,040191.78 million190.15 millionOptionableGMABGenmab A/S2,682641.54 million631.66 millionOptionableGNMSFGenmab A/S2,68266.07 million65.06 millionNot OptionableUCBJFUCB9,083189.02 millionN/ANot OptionableBMRN, GNMSF, UCBJF, GMAB, and ALNY HeadlinesRecent News About These CompaniesUCB (OTCMKTS:UCBJF) Shares Gap Down - Here's WhyJuly 10 at 4:04 PM | marketbeat.comUCB (OTCMKTS:UCBJF) Share Price Crosses Above Fifty Day Moving Average - Should You Sell?July 4, 2025 | marketbeat.comUCB (OTCMKTS:UCBJF) Shares Gap Down - Should You Sell?June 30, 2025 | marketbeat.comUCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life SciencesMay 20, 2025 | finance.yahoo.comUnited Community Banks, Inc. (UCB) Q1 2025 Earnings Call TranscriptApril 22, 2025 | seekingalpha.comUCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025April 3, 2025 | finance.yahoo.comUCB Convening Notice to the General Meeting of the Shareholders 2025March 21, 2025 | finance.yahoo.comUCB price target raised to EUR 220 from EUR 130 at BerenbergFebruary 25, 2025 | markets.businessinsider.comUCB price target raised to EUR 200 from EUR 105 at Morgan StanleyFebruary 12, 2025 | markets.businessinsider.comUCB assumed with an Equal Weight at Morgan StanleyFebruary 12, 2025 | markets.businessinsider.comUCB SA (0NZT) Receives a Hold from Kepler CapitalFebruary 2, 2025 | markets.businessinsider.comUCB SA (0NZT) Gets a Buy from BarclaysJanuary 27, 2025 | markets.businessinsider.comUnited Community Banks, Inc. (UCB) Q4 2024 Earnings Call TranscriptJanuary 22, 2025 | seekingalpha.comUCB SA (0NZT) Receives a Buy from BarclaysJanuary 16, 2025 | markets.businessinsider.comUCB price target raised to EUR 215 from EUR 200 at Deutsche BankNovember 12, 2024 | markets.businessinsider.comUBS Remains a Buy on UCB SA (0NZT)November 4, 2024 | markets.businessinsider.comArtisan Global Equity Fund Q3 2024 CommentaryOctober 25, 2024 | seekingalpha.comArtisan International Fund Q3 2024 CommentaryOctober 25, 2024 | seekingalpha.comBimzelx Powers UCB To New Heights: Deep Dive Into The Company's Growth StrategyOctober 18, 2024 | seekingalpha.comBarclays Keeps Their Buy Rating on UCB SA (0NZT)October 7, 2024 | markets.businessinsider.comUCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic ArthritisSeptember 30, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBMRN, GNMSF, UCBJF, GMAB, and ALNY Company DescriptionsAlnylam Pharmaceuticals NASDAQ:ALNY$322.64 +1.77 (+0.55%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$322.17 -0.47 (-0.15%) As of 07/10/2025 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.BioMarin Pharmaceutical NASDAQ:BMRN$58.82 -0.85 (-1.42%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$58.90 +0.09 (+0.14%) As of 07:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.Genmab A/S NASDAQ:GMAB$21.86 +0.28 (+1.30%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$21.83 -0.03 (-0.13%) As of 07:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Genmab A/S OTCMKTS:GNMSF$212.55 -2.45 (-1.14%) As of 07/10/2025 09:33 AM EasternGenmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.UCB OTCMKTS:UCBJF$203.85 0.00 (0.00%) As of 07/10/2025 02:37 PM EasternUCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.